It’s with truly bittersweet feelings that I share the news today that Nicole Lambert, our Chief Operating Officer, will be retiring from full-time service at Myriad after 22 years to spend more time with her family and pursue other professional opportunities. She will continue working with us as a senior advisor on key projects through at least the end of March 2024. Over the next few weeks, we will work on the transition plan and keep you informed of any organizational changes.

Since 2001, Nicole has been instrumental in building Myriad Genetics into the company we know today, and continually advancing our mission to improve patients’ lives. From the start of her career as a genetic counselor, she’s always been passionate about helping others, and deep down, she knew working at Myriad would allow her to pursue that passion. While in college, Nicole turned on the radio one day and learned about a Utah company sequencing the BRCA gene. You can guess what happened next.

Nicole started at Myriad as an account executive and regional medical specialist in Texas. From day one, her compassion and drive to innovate was felt by many teammates. I also was deeply impressed with her passion and dedication, from the first day I worked with her. Nicole has played an integral role in leading Myriad’s growth, from thousands of patients served in the early days to many millions today. Nicole’s wisdom, knowledge, and compassion have guided us all every day.

Thank you, Nicole, for everything you’ve done for Myriad, for supporting me as my North Star the last three years and helping to lead the entire industry. We are all incredibly excited for you and your family to have more time together and for your commitment to remain a key advisor to me and the entire team.

Paul Diaz
President & CEO

Here are a few words that Nicole wanted to share with all of you:

To my Myriad Family,

I came to Myriad to make a difference in people’s lives, and I know we’ve done that together. When I joined, I didn’t know that I’d get to do that with colleagues who would soon become like family to me. I am so proud of what we’ve been able to accomplish together. Genetic testing is more accessible than ever before, we offer a full portfolio of tests that are relevant throughout a patient’s lifetime, and families enjoy more time together because of what we do. While I will greatly miss working with all of you, I’m excited for Myriad’s future, and wish you all much success to come.

All the best,